Nelson VM - Search Results

1

Status of targeted therapies in the adjuvant treatment of colon cancer.

Nelson VM, Benson AB 3rd. Nelson VM, et al. J Gastrointest Oncol. 2013 Sep;4(3):245-52. doi: 10.3978/j.issn.2078-6891.2013.035. J Gastrointest Oncol. 2013. PMID: 23997937 Free PMC article.

2

Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy.

Nelson VM, Benson AB 3rd. Nelson VM, et al. Curr Oncol Rep. 2013 Apr;15(2):152-61. doi: 10.1007/s11912-013-0297-5. Curr Oncol Rep. 2013. PMID: 23381584 Review.

3

Epidemiology of Anal Canal Cancer.

Nelson VM, Benson AB 3rd. Nelson VM, et al. Surg Oncol Clin N Am. 2017 Jan;26(1):9-15. doi: 10.1016/j.soc.2016.07.001. Surg Oncol Clin N Am. 2017. PMID: 27889039 Review.

4

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.

Nelson V, Ziehr J, Agulnik M, Johnson M. Nelson V, et al. Onco Targets Ther. 2013;6:135-43. doi: 10.2147/OTT.S23165. Epub 2013 Mar 5. Onco Targets Ther. 2013. PMID: 23493883 Free PMC article.

5

Paradigm of polyendocrine therapy in endocrine responsive breast cancer: the role of fulvestrant.

Nelson V, Rademaker A, Kaklamani V. Nelson V, et al. Chin Clin Oncol. 2013 Mar;2(1):10. doi: 10.3978/j.issn.2304-3865.2012.09.04. Chin Clin Oncol. 2013. PMID: 25841451 Free article. No abstract available.

6

Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.

Cowan M, Swetzig WM, Adorno-Cruz V, Pineda MJ, Neubauer NL, Berry E, Lurain JR, Shahabi S, Taiym D, Nelson V, O'Shea KL, Kocherginsky M, Matei D. Cowan M, et al. Gynecol Oncol. 2021 Oct;163(1):57-63. doi: 10.1016/j.ygyno.2021.08.005. Epub 2021 Aug 18. Gynecol Oncol. 2021. PMID: 34419285 Clinical Trial.

7

Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer.

Nelson V, Altman JK, Platanias LC. Nelson V, et al. Expert Opin Investig Drugs. 2013 Jun;22(6):715-22. doi: 10.1517/13543784.2013.787066. Epub 2013 Apr 2. Expert Opin Investig Drugs. 2013. PMID: 23544840 Review.

8

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.

Shah AN, Flaum L, Helenowski I, Santa-Maria CA, Jain S, Rademaker A, Nelson V, Tsarwhas D, Cristofanilli M, Gradishar W. Shah AN, et al. J Immunother Cancer. 2020 Feb;8(1):e000173. doi: 10.1136/jitc-2019-000173. J Immunother Cancer. 2020. PMID: 32060053 Free PMC article. Clinical Trial.

9

A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.

Karmali R, Galvez C, Hamadani M, Gordon L, Winter J, Ma S, Nelson V, Fenske TS, Shah NN, Jagadeesh D, Klein A, Helenowski I, Chen R, Mi X, Petrich A, Evens AM, Pro B. Karmali R, et al. Blood Adv. 2024 Apr 9;8(7):1612-1620. doi: 10.1182/bloodadvances.2023011369. Blood Adv. 2024. PMID: 38237077 Free PMC article. Clinical Trial.

10

A Phase II Trial of Bevacizumab in Patients with Recurrent/Progressive Solid Tumor Brain Metastases That Have Progressed Following Whole-Brain Radiation Therapy.

Dixit K, Singer L, Grimm SA, Lukas RV, Schwartz MA, Rademaker A, Zhang H, Kocherginsky M, Chernet S, Sharp L, Nelson V, Raizer JJ, Kumthekar P. Dixit K, et al. Cancers (Basel). 2024 Jun 4;16(11):2133. doi: 10.3390/cancers16112133. Cancers (Basel). 2024. PMID: 38893252 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters